Cargando…
The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications
The US Food and Drug Administration (FDA) is open to accepting real‐world evidence (RWE) to support its assessment of medical products. However, RWE stakeholders lack a shared understanding of FDA’s evidentiary expectations for the use of RWE in applications for new drugs and biologics. We conducted...
Autores principales: | Purpura, Christina A., Garry, Elizabeth M., Honig, Nicholaas, Case, Abigail, Rassen, Jeremy A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299054/ https://www.ncbi.nlm.nih.gov/pubmed/34726771 http://dx.doi.org/10.1002/cpt.2474 |
Ejemplares similares
-
USING REAL-WORLD EVIDENCE TO SUPPORT THE FDA REGULATORY APPROVAL: METHODOLOGICAL CONSIDERATIONS
por: Lu, Kevin, et al.
Publicado: (2022) -
FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023) -
Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020) -
Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022) -
Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)